BJDRCT
Durability of response to icotrokinra in adults with moderate-to-severe plaque psoriasis
1-year results from the phase III, placebo- and active comparator-controlled ICONIC-ADVANCE 1 and ICONIC-ADVANCE 2 trials.
ConclusionOnce-daily icotrokinra provided robust, durable skin clearance and symptom improvement, with no safety signals, through week 52 in adults with moderate-to-severe plaque psoriasis. Participants transitioning from placebo or deucravacitinib to icotrokinra achieved similar increased response rates to participants who were randomized to icotrokinra through week 52. Our findings support icotrokinra as a systemic therapy with long-term robust disease control and a favourable safety profile.
Stein Gold L, Armstrong AW, … senior author Bissonnette RBritish Journal of Dermatology